Literature DB >> 12792360

HIV risk reduction in a cohort of injecting drug users in Bangkok, Thailand.

Kachit Choopanya1, Don C Des Jarlais, Suphak Vanichseni, Philip A Mock, Dwip Kitayaporn, Udomsak Sangkhum, Boonrawd Prasithiphol, Krit Hiranrus, Frits van Griensven, Jordan W Tappero, Timothy D Mastro.   

Abstract

OBJECTIVE: To determine changes in risk behavior in relation to study participation among injecting drug users (IDUs) in Bangkok, Thailand.
METHODS: During 1995-1996, 1,209 HIV-seronegative IDUs were recruited from Bangkok Metropolitan Administration drug abuse treatment programs to participate in a prospective cohort study. Study visits occurred every 4 months, at which the participants underwent an interview to assess risk behavior and HIV counseling and testing. Eight hundred nine of the IDUs were considered "long-term" participants, who remained in the study through at least the first four scheduled follow-up visits (16 months). Injection risk behavior at each study visit was measured on a four-point scale strongly associated with incident HIV infections in the cohort. Individual regression slopes were used to assess changes in injection risk behavior (risk increase, no change, or risk reduction).
RESULTS: Of the 806 long-term study participants, 79% showed declines, 4% showed no change, and 17% showed increases in injection risk behavior. The percentage of participants in the highest-risk category (injecting daily or more frequently and sharing needles and syringes) declined from 42% at baseline to 3% at the final follow-up visit. Being in methadone maintenance treatment was associated with stable low rates of injection risk behavior, while recruitment from the 45-day detoxification treatment was associated with reductions in injection risk behavior. The risk reduction was independent of decline in risk behavior among IDUs in the community at large.
CONCLUSIONS: Participation in this cohort study was associated with substantial declines in injection risk behavior. This information is important in the evaluation of possible adverse behavioral effects of participation in future preventive HIV vaccine trials including IDUs, particularly in developing country settings.

Entities:  

Mesh:

Year:  2003        PMID: 12792360     DOI: 10.1097/00126334-200305010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

Review 1.  Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users.

Authors:  Nicholas Meader; Ryan Li; Don C Des Jarlais; Stephen Pilling
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

2.  A cross-sectional assessment of utilization of addiction treatment among injection drug users in Kabul, Afghanistan.

Authors:  Catherine S Todd; Abdullah M S Abed; Paul T Scott; Naqibullah Safi; Kenneth C Earhart; Steffanie A Strathdee
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

3.  Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S.

Authors:  Emily Faye White; Richard S Garfein; Kimberly C Brouwer; Remedios Lozada; Rebeca Ramos; Michelle Firestone-Cruz; Saida G Pérez; Carlos Magis-Rodríguez; Carlos J Conde-Glez; Steffanie A Strathdee
Journal:  Salud Publica Mex       Date:  2007 May-Jun

4.  A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.

Authors:  Sandra A Springer; Robert D Bruce
Journal:  J Opioid Manag       Date:  2008 Mar-Apr

5.  Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective study.

Authors:  Wen Chen; Yinghua Xia; Yan Hong; Brian J Hall; Li Ling
Journal:  Harm Reduct J       Date:  2013-10-10

6.  Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study.

Authors:  Rab Nawaz Samo; Ajmal Agha; Sharaf Ali Shah; Arshad Altaf; Ashraf Memon; Meridith Blevins; Han-Zhu Qian; Sten H Vermund
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.